Financial Counselors Inc. Raises Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Financial Counselors Inc. increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,147 shares of the company’s stock after buying an additional 13,675 shares during the period. Financial Counselors Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,546,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in TEVA. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $50,000. Ameliora Wealth Management Ltd. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $66,000. IFP Advisors Inc raised its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after buying an additional 1,960 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $104,000. Finally, Assetmark Inc. boosted its position in Teva Pharmaceutical Industries by 1,370.3% during the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock valued at $115,000 after acquiring an additional 4,851 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Down 1.1 %

TEVA stock opened at $15.52 on Friday. The stock has a market capitalization of $17.60 billion, a PE ratio of -10.71, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm has a 50 day moving average of $17.35 and a 200 day moving average of $18.14.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on TEVA. Bank of America decreased their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Finally, UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.